Spinal Muscular Atrophy (SMA)

Introduction

Spinal muscular atrophy, usually shortened to SMA, is a genetic condition that gradually weakens the muscles used for movement, breathing, and swallowing. It happens because certain nerve cells in the spinal cord, called motor neurons, do not work properly and slowly die. Without these nerve cells sending signals, muscles do not get used, and over time they become weaker and smaller.

SMA can affect babies, children, teenagers, and adults. The age at which it first appears, and how quickly it progresses, varies widely between people. Some forms are very severe and appear in the first months of life. Others are milder and may not be diagnosed until adulthood.

If you or your child has recently been diagnosed with SMA, this article is written for you. It explains what SMA is, why it happens, the different types, how it is diagnosed, and what current treatment and care look like. The picture for people with SMA has changed dramatically in recent years. New disease-modifying therapies, earlier diagnosis, and well-organised multidisciplinary care have improved survival and quality of life in ways that were not possible even a decade ago.

What Is Spinal Muscular Atrophy?

SMA is a disease of the motor neurons. Motor neurons are the nerve cells that carry signals from the brain and spinal cord out to the muscles. When you decide to move your arm, lift your head, swallow, or take a breath, motor neurons are doing the work of telling your muscles what to do.

SMA does not affect intelligence, thinking, or sensation. Children with SMA are typically bright, alert, and aware of their surroundings. The senses — sight, hearing, touch, taste, and smell — are not affected. The condition mainly affects voluntary muscle movement, breathing muscles, and the muscles used for swallowing.

The most common form of SMA is caused by a problem in a gene called SMN1 (survival motor neuron 1). This gene makes a protein called SMN, which motor neurons need to stay alive and healthy. When both copies of SMN1 are missing or faulty, the body cannot produce enough SMN protein, and motor neurons begin to die.

Most people also have a second, nearby gene called SMN2. This gene makes a small amount of SMN protein. The number of SMN2 copies a person has — usually between one and four — partly predicts how severe their SMA will be. More SMN2 copies generally means a milder form.

Types of SMA

Type 0 (prenatal onset)

Type 0 is the rarest and most severe form. Signs begin before birth, with the mother often noticing reduced foetal movements. Babies are born with severe weakness, joint contractures, and serious breathing problems. Without treatment, survival is very limited.

Type 1 (Werdnig-Hoffmann disease)

Type 1 is the most common severe form. Symptoms appear before six months of age. Babies have severe muscle weakness and floppiness (hypotonia), cannot sit without support, and have difficulty swallowing and breathing. Without treatment, most babies with type 1 historically did not survive past the age of two. Disease-modifying therapies have changed this outlook substantially, especially when started early.

Type 2 (intermediate SMA)

Type 2 begins between about six and eighteen months of age. Children are able to sit independently at some point but cannot stand or walk without support. They often develop scoliosis (curvature of the spine), breathing difficulties over time, and joint stiffness. Many people with type 2 live into adulthood, particularly with good supportive care.

Type 3 (Kugelberg-Welander disease)

Type 3 begins after eighteen months of age, sometimes in childhood and sometimes in the teenage years. Children with type 3 are able to walk independently, at least for a time. Walking may become harder over the years, and some people lose the ability to walk in adolescence or adulthood. Life expectancy with type 3 is typically normal or near-normal.

Type 4 (adult-onset SMA)

Type 4 begins in adulthood, usually after the age of thirty. Weakness develops slowly, often in the legs first. Most people with type 4 remain able to walk, although they may need aids over time. Life expectancy is generally normal.

Other forms

A small number of SMA cases are caused by problems in genes other than SMN1. These include conditions such as SMA with respiratory distress (SMARD1) and certain X-linked forms. These are rare and are managed in specialised neuromuscular centres.

Causes and Genetics

SMA caused by SMN1 changes is inherited in what is called an autosomal recessive pattern. This means a child develops SMA only if they inherit a faulty copy of the gene from both parents. Each parent is usually a healthy carrier, meaning they have one working copy and one faulty copy and have no symptoms themselves.

• There is a 1 in 4 chance with each pregnancy that the child will have SMA
• There is a 2 in 4 chance the child will be a carrier without symptoms
• There is a 1 in 4 chance the child will neither have SMA nor be a carrier

Carrier status is more common than many people realise. Genetic counselling is helpful for families who have a child with SMA and are considering future pregnancies, and for relatives of people with SMA who want to understand their own carrier status. Carrier screening and prenatal genetic testing are available in specialist centres.

SMA is not caused by anything the parents did or did not do during pregnancy. It is not caused by diet, stress, vaccines, or any environmental exposure. It is a genetic condition present from conception.

Signs and Symptoms

The signs of SMA depend on the type and the age of onset. For families who already have a diagnosis, this section helps explain what is happening in the body and what changes to watch for as the condition progresses or responds to treatment.

Common features across SMA types include:

• Muscle weakness, usually more pronounced in muscles closer to the centre of the body (hips, shoulders, thighs) than in the hands and feet
• Low muscle tone (hypotonia), especially in infants — babies feel floppy when held
• Difficulty achieving or maintaining motor milestones such as head control, sitting, standing, or walking
• Muscle wasting — muscles look smaller than expected
• Tongue fasciculations — small flickering movements of the tongue, often seen in type 1
• Tremor of the fingers, more common in older children and adults with milder types
• Swallowing and feeding difficulties, particularly in more severe types
• Breathing difficulties, especially during sleep or with respiratory infections
• Scoliosis — sideways curvature of the spine, common in non-walking children as they grow
• Joint contractures — tightness around joints that limits movement

People with SMA typically have normal cognition, normal facial expression, and normal eye movements. Sensation is not affected. The bladder and bowel are usually not directly affected by the disease itself, although mobility limitations can make toileting more complex.

Diagnosis

SMA is diagnosed through a combination of clinical examination and genetic testing. In countries with newborn screening for SMA, the diagnosis is increasingly made before symptoms appear, which allows treatment to begin very early.

Clinical assessment

A paediatric neurologist or neuromuscular specialist examines the child or adult for the typical pattern of weakness, low tone, reduced reflexes, and muscle wasting. They take a careful history of motor milestones and any family history of neuromuscular disease.

Genetic testing

The definitive test for the most common form of SMA is a blood test that looks for the deletion or mutation of both copies of the SMN1 gene. This test also typically counts the number of SMN2 copies, which helps predict severity and guides treatment decisions.

If the SMN1 test is negative but SMA is still suspected based on clinical features, further genetic testing for rarer forms may be done.

Other tests

Before genetic testing was widely available, doctors often used:

• Electromyography (EMG) — a test that records the electrical activity of muscles
• Nerve conduction studies — to assess how well nerves carry signals
• Muscle biopsy — a small sample of muscle examined under a microscope
• Blood creatine kinase (CK) — usually normal or only mildly raised in SMA, unlike in muscular dystrophies

These tests are still used in some situations, particularly when the picture is unclear or when looking for other neuromuscular conditions. However, genetic testing is now the first-line diagnostic step in most centres.

Newborn screening

Several countries have added SMA to their newborn screening programmes, allowing diagnosis within the first days of life. Early treatment — before significant motor neuron loss — gives the best chance of preserving motor function. Newborn screening for SMA is not yet universally available in India, but the science behind the rationale for early diagnosis is well established and widely accepted.

Treatment and Management

Care for SMA has two main parts: disease-modifying therapies that target the underlying genetic problem, and multidisciplinary supportive care that addresses the day-to-day effects of the disease. Both are important. Disease-modifying therapy alone is not a substitute for good respiratory, nutritional, orthopaedic, and rehabilitation care.

Disease-modifying therapies

Three disease-modifying therapies have changed the clinical landscape for SMA. Each works in a different way to increase the amount of functional SMN protein in motor neurons. None of them cures SMA, but each has been shown in clinical trials to slow progression and, particularly in early-treated infants, to allow motor milestones that would not otherwise have been reached.

Nusinersen is an antisense oligonucleotide. It works by modifying how the SMN2 gene is read, so that it produces more functional SMN protein. It is given as an injection into the spinal fluid through a lumbar puncture. After an initial loading schedule, it is given every four months for as long as it continues to be of benefit.

Onasemnogene abeparvovec is a one-time gene therapy. It delivers a working copy of the SMN1 gene to motor neurons using a modified harmless virus. It is given as a single intravenous infusion. It is generally used in young children, with eligibility based on weight, age, and specific clinical criteria.

Risdiplam is an oral medicine taken as a daily liquid. Like nusinersen, it works on the SMN2 gene to increase SMN protein production. It is approved for a wide age range, including infants and adults.

Which therapy is appropriate for a specific person depends on age, weight, type of SMA, SMN2 copy number, level of motor function, and other factors. Major neuromuscular societies emphasise that the decision is individualised and made in consultation with a specialist neuromuscular team. Long-term data continue to accumulate, and treatment guidelines are updated as new evidence emerges.

Multidisciplinary supportive care

Physiotherapy and rehabilitation: Physiotherapy aims to maintain joint range of motion, prevent contractures, support motor function, and help with mobility aids. Regular stretching, positioning, and gentle exercise are part of daily life for many people with SMA. Walking aids, standing frames, and powered wheelchairs allow children and adults to be active and engaged.

Respiratory care: Weak breathing muscles and a weak cough are central problems in SMA, especially in more severe types. Respiratory care includes:

• Regular monitoring of breathing strength and overnight oxygen levels
• Cough assist devices that help clear secretions from the chest
• Non-invasive ventilation (such as BiPAP) used overnight or during illness
• In some cases, tracheostomy and longer-term ventilation, depending on the family's goals of care
• Prompt treatment of chest infections, which can become serious quickly
• Vaccinations, including against influenza and respiratory syncytial virus where appropriate

Nutrition and feeding: Many children with SMA, particularly types 1 and 2, have difficulty with feeding due to weak swallowing muscles. Feeding can be slow, tiring, and sometimes unsafe because of the risk of food or liquid going into the airway. A speech and language therapist and a dietitian assess swallowing and nutrition. Some children benefit from a feeding tube (such as a gastrostomy) to ensure safe, adequate nutrition and to reduce the burden of long feeds.

Orthopaedic care: Scoliosis is common, especially in children who are not walking. Hip dislocation, contractures, and limb deformities can also develop. Orthopaedic specialists monitor the spine and joints, prescribe braces where appropriate, and consider surgery (such as spinal fusion) when curvature progresses and affects comfort, sitting, or breathing.

Bone health: Reduced movement and weight-bearing puts children and adults with SMA at higher risk of low bone density and fractures. Vitamin D, calcium, weight-bearing where possible, and monitoring of bone health are part of routine care.

Speech and language therapy: Beyond swallowing, speech therapy can support communication, including the use of alternative and augmentative communication for children with significant motor limitations.

Occupational therapy: Occupational therapists help with adaptations for everyday tasks — eating, dressing, writing, using technology — and support school participation and independent living.

Lifestyle and Self-Management

Living well with SMA is not only about medical appointments. It involves daily routines that protect health and support participation in school, work, and family life.

Daily routines

Chest care during illness

Even a mild cold can become serious in a person with SMA because of weak breathing and cough. Families are usually taught early signs of respiratory infection — faster breathing, increased work of breathing, lower energy, change in colour, fever — and an action plan for using cough assist, non-invasive ventilation, and seeking urgent medical review.

Vaccinations and infection prevention

Routine childhood vaccinations, seasonal influenza vaccination, and other vaccines as recommended for the person's age are important. During respiratory illness seasons, careful hand hygiene and avoiding contact with sick visitors help reduce risk.

Education and inclusion

Children with SMA generally have typical cognitive ability and benefit from full participation in school. Adaptations may include accessible classrooms, assistive technology, support for writing and physical activities, and a school plan that addresses toileting, feeding, and medical needs. Many adults with SMA work, study, and live independently with appropriate support.

Emotional well-being

SMA affects the whole family. Parents, siblings, and people living with SMA can all benefit from emotional support. Peer connections through SMA family networks and patient organisations can be valuable. Mental health support is part of comprehensive care.

Monitoring and Follow-up

People with SMA are typically followed by a neuromuscular team that coordinates care across specialties. The frequency of visits depends on age, type, and stability.

Routine monitoring usually includes:

• Motor function assessments using standardised scales
• Respiratory function tests, including lung capacity in older children and adults, and overnight studies where indicated
• Nutritional status, growth, and weight monitoring
• Spine and joint examinations, with imaging as needed
• Bone health checks
• Review of equipment, mobility aids, and home adaptations
• Assessment of response to disease-modifying therapy

Complications

The complications most commonly seen in SMA reflect the impact of muscle weakness on the body's everyday functions.

• Respiratory infections, which can be serious and recurrent in more severe types
• Respiratory failure, particularly during sleep or illness in types 1 and 2 without ventilatory support
• Swallowing difficulties and aspiration, where food or liquid enters the airway
• Failure to thrive in young children with feeding difficulties
• Scoliosis and chest wall deformity, which can in turn worsen breathing
• Joint contractures and hip dislocation
• Reduced bone density and fractures
• Pressure sores in people with very limited movement
• Fatigue, which is common across all types

Many of these complications are reduced by early, coordinated multidisciplinary care and by disease-modifying therapy.

Living with SMA

The way SMA is lived varies enormously. A child with type 1 who started treatment as a newborn through screening may grow up sitting, standing, and even walking — outcomes that were not seen before the new therapies. A teenager with type 3 may use a wheelchair part-time, go to university, and live independently. An adult with type 4 may have mild weakness that becomes more noticeable over decades.

Common themes across the SMA community include:

• The importance of routine and planning — for school, travel, equipment, and medical care
• The value of skilled multidisciplinary care that does not stop at one specialty
• The role of assistive technology in enabling participation and independence
• Strong family and peer networks
• Honest conversations with the care team about goals, expectations, and difficult decisions

For families with a child newly diagnosed with a severe type of SMA, the early weeks often involve a great deal of information at once. Care teams, palliative care specialists, and patient organisations can help families think through choices about ventilation, feeding, and treatment in line with their values.

SMA in Adults

Most articles about SMA focus on children because that is when most people are diagnosed. Adults with SMA, however, are an important and growing group — both adults who were diagnosed as children and have grown into adulthood, and adults with milder forms (type 3 or 4) who may have been diagnosed later in life.

Adult care priorities include:

• Maintaining mobility, strength, and independence with physiotherapy and equipment
• Ongoing respiratory monitoring, particularly during sleep
• Bone health, weight management, and general health screening
• Mental health and social support
• Family planning and genetic counselling
• Workplace and home adaptations
• Discussion of disease-modifying therapy, which is approved for adult use

Pregnancy is possible for women with milder forms of SMA but requires careful planning with neuromuscular, obstetric, and anaesthetic specialists, particularly regarding respiratory function and delivery planning.

Preventing Complications

While SMA itself cannot be prevented in someone who has the genetic change, many of its complications can be reduced.

• Early diagnosis and early disease-modifying therapy, where appropriate, preserve more motor neurons
• Proactive respiratory care reduces the risk of severe infection and respiratory failure
• Good nutrition and safe swallowing reduce the risk of aspiration and failure to thrive
• Regular physiotherapy and orthopaedic care slow the progression of contractures and scoliosis
• Vaccinations protect against serious infection
• Family genetic counselling helps relatives understand their carrier status and reproductive options

When to Seek Urgent Care

Families and adults living with SMA should have a clear plan with their care team for when to seek urgent medical attention. Reasons to seek prompt care include:

• New or worsening difficulty breathing, faster breathing, or increased work of breathing
• A change in colour (pale, blue, or grey)
• A new or worsening cough, fever, or chest infection symptoms
• Choking or new swallowing difficulty
• Significant reduction in feeding or fluid intake
• Unusual sleepiness, drowsiness, or low responsiveness
• A fall or suspected fracture, especially given the increased risk of low bone density
• Any sudden, unexplained change in strength or function

People with SMA and their families often become very accurate observers of small changes. Care teams generally encourage families to trust those observations and seek review early rather than late.

Frequently Asked Questions

Is SMA curable?

SMA is not currently curable, but it is treatable. Disease-modifying therapies can significantly slow progression and, particularly when started very early, allow motor milestones that previously were not seen. Combined with skilled multidisciplinary care, outcomes for SMA today are very different from what they were a decade ago.

Does SMA affect intelligence?

No. SMA does not affect cognition, learning, or sensation. Children with SMA typically follow a normal cognitive development trajectory and benefit from full participation in education.

How is SMA different from muscular dystrophy?

Both are neuromuscular conditions, but the underlying problem is different. In SMA, the motor nerve cells in the spinal cord are affected. In muscular dystrophies, the muscle fibres themselves have a problem. The genes involved, the inheritance patterns, and the typical clinical features differ.

Did we cause SMA in our child?

No. SMA is a genetic condition. Parents who are carriers usually have no symptoms and no way of knowing they are carriers unless they are tested. Nothing about pregnancy, diet, or lifestyle causes SMA.

If we have one child with SMA, what is the chance our next child will also have it?

If both parents are carriers, there is a 1 in 4 chance with each pregnancy that the child will have SMA. Genetic counselling helps families understand their specific situation and the testing options available.

How are the disease-modifying therapies chosen?

The choice between nusinersen, onasemnogene abeparvovec, and risdiplam depends on factors including age, weight, type of SMA, SMN2 copy number, current motor function, prior treatments, and what is appropriate in a specific health system. The decision is made in consultation with a neuromuscular specialist team.

Can someone with SMA live a full life?

Many people with SMA, particularly those with milder types or those who started disease-modifying therapy early, live full and meaningful lives — going to school, working, having relationships, and raising families. For severe types, the picture is more variable and depends on many factors, including timing of diagnosis, access to treatment, and the family's goals of care.

Is exercise safe in SMA?

Activity is encouraged within the person's safe range. Care teams — particularly physiotherapists — tailor activity to the individual, balancing the goals of maintaining strength and joint mobility with avoiding excessive fatigue. Specific exercise plans should be discussed with the team.

Are there any new treatments coming?

SMA is an active area of research. New therapies, combinations of existing therapies, and approaches targeting different aspects of the disease are being studied. Specialist centres can advise on whether clinical trials may be relevant for a particular person.

Conclusion

Spinal muscular atrophy is a complex genetic condition, and a diagnosis — whether in a newborn, a child, or an adult — raises many questions. The outlook for people with SMA today is genuinely different from what it was even ten years ago. Disease-modifying therapies have changed what is possible. Coordinated multidisciplinary care, attentive respiratory and nutritional management, and assistive technology allow children and adults with SMA to participate, learn, work, and connect.

Care is most effective when it is individualised, when families and patients are partners in decisions, and when the team around the person with SMA is experienced in the condition. The treatments, monitoring schedules, and supports described here are starting points for a conversation with a neuromuscular specialist team, who can build a plan that fits the specific person and family.